Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications
recent articles
Tempus’ multimodal foundation model offers diagnostic-grade precision for cancer detection and unlocks broader applications predicting biomarker status and patient prognosis CHICAGO, August 4, 2026 — Tempus AI, Inc. (NASDAQ: TEM), a...
NEW YORK--(BUSINESS WIRE)--Ataraxis AI, a frontier clinical artificial intelligence (AI) company developing AI-powered tools for oncology, today announced that its laboratory has received accreditation from the College of American...
August 25, 2026 - Stratipath, a leader in AI-based precision diagnostics for breast cancer, and Aiforia, a pioneer in AI-driven diagnostics in pathology, today announced a strategic partnership. This collaboration aims to provide pathologists...
From the Gestalt blog: Healthcare IT isn’t shrinking, it’s resetting. After the surge of pandemic-era hiring, many health systems are stepping back and asking a hard question: does more headcount actually make us more agile? In 2026,...
From Proscia on LinkedIn When evaluating an enterprise pathology platform, many life sciences organizations and diagnostic laboratories focus on the features it offers. This makes sense since scientists and pathologists will rely on that...
Bioptimus to use Cancer Research Horizons’ data to train and evaluate its AI foundation model Third partnership since Bioptimus launched ground-breaking STELA initiative in March Deal adds Bioptimus' first UK patient cohort to...
